Envista, formerly Danaher Group’s dental division, was spun off in 2019 due to its relatively small scale within the conglomerate.

The company operates globally, with 52% of revenue from North America and 22% from developing markets, including China. Its flagship brand, Nobel Biocare, is a leader in prosthetic dental implants, which, alongside lower-spec alternatives, account for 40% of revenue. Orthodontics contributes 24%, driven by brackets and wires, which continue to expand in emerging markets. Envista has also gained traction with Spark, its clear aligner system competing with market leader Invisalign.

The remaining business comprises dental consumables and diagnostic equipment. Envista is a pioneer in 3D imaging, with one of the largest installed bases of dental imaging devices globally.